A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics

Cancer Research and Treatment · Published 2026-07-15 · DOI 10.4143/crt.2025.1417

Free full text

Authors (2)

Jingbo Du, Lin Zhu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Du, J., Zhu, L. (2026). A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.1417

Related articles

• Tumor-Intrinsic Hepatocyte Arm-Level Genomic States Shape Immunotherapy Response Heterogeneity in Hepatocellular Carcinoma · Cancer Research and Treatment · 2026 · Same journal
• Therapeutic Potential of Engineered Stem Cell Line with Chemokine Receptors and TRAIL/CD::UPRT in Glioblastoma Treatment · Cancer Research and Treatment · 2026 · Same journal
• Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023 · Cancer Research and Treatment · 2026 · Same journal
• A Prospective Study of Non‑Treating Medical Institution Use for Supportive Care During Adjuvant Chemotherapy After Curative Surgery (PRO-SUCCESS) · Cancer Research and Treatment · 2026 · Same journal
• A Phase I/II Trial to Evaluate the Safety and Efficacy of Continuous Positive Airway Pressure in Volumetric Modulated Arc Therapy for Breast Cancer · Cancer Research and Treatment · 2026 · Same journal
• Individual SGLT-2 Inhibitors and Risk of New-Onset Cancer in Type 2 Diabetes: A Nationwide Population-Based Cohort Study · Cancer Research and Treatment · 2026 · Same journal
• Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program · Cancer Research and Treatment · 2026 · Same journal
• Biomarker Testing Practices for Non-small Cell Lung Cancer: Survey Insights from South Korean Pathology Laboratories · Cancer Research and Treatment · 2026 · Same journal
• A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations · Cancer Research and Treatment · 2026 · Same journal
• Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19) · Cancer Research and Treatment · 2026 · Same journal